Clinical Trial Update: Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C [Phase 3]

View source ↗

Summary

This document reports the completion of a Phase 3 safety and efficacy trial comparing Peginterferon Lambda-1a to Peginterferon Alfa-2a plus ribavirin in patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Peginterferon alfa-2a (peginterferon alfa-2a)
• Peginterferon lambda-1a (peginterferon lambda-1a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C Virus (HCV) | Phase 3 | Status: COMPLETED